SLC5A2 and type 2 diabetes mellitus: In addition to the cornerstone medications (angiotensin converting enzyme inhibitors and angiotensin II receptor blockers) for which renoprotective effects were revealed in patients with type 2 diabetes [14], several recent trials showed the renoprotective effects of sodium-glucose cotransporter-2 (SGLT2) inhibitors [15–17].